Travere Therapeutics, Inc. (TVTX) stock
Close on Nov 12, 2026Market cap $4.86BP/E –Yield –
Travere Therapeutics, Inc. grew revenue 49.4% to $651.04M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $4.86B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $4.86B
- P/E ratio
- –
- Price to sales
- 7.47
- Price to book
- 215.20
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $651.04M
- Net income
- -$121.51M
- EPS, diluted
- -$1.29
- Book value per share
- $0.24
- Diluted shares
- 95M
Trading
- Next earnings
- Feb 18, 2027 (estimated, after the close)
- Previous close
- $52.04
- Open
- $51.79
- Day's range
- $51.11 – $52.52
- Volume
- 590,308
- Average volume (20 days)
- 2,296,792
- Index membership
- Russell 2000 (since Dec 2020), Russell 3000 (since Nov 2020)
- Beta (5 years)
- 1.14
- 52-week range
- $22.59 – $68.73
- RSI (14 days)
- 46.9
- Volatility (1 year)
- 62.6%
- Relative volume
- 0.34×
- WACC
- 10.6%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TVTX | S&P 500 | Difference | TVTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.9% | -2.7% | +1.8 pts | ||
| 3 months | -17.1% | -1.7% | −15.3 pts | ||
| Year to date | +34.9% | +11.9% | +23.0 pts | ||
| 1 year | +41.4% | +12.0% | +29.4 pts | ||
| 3 years | +824.0% | +78.2% | +745.8 pts | +109.8% | +21.2% |
| 5 years | +73.0% | +73.2% | −0.3 pts | +11.6% | +11.6% |
| 10 years | +143.7% | +309.6% | −166.0 pts | +9.3% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Travere Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- Results
- Results
About Travere Therapeutics
Pharmaceutical Preparations
This biopharmaceutical company identifies, develops, and delivers therapies for rare kidney and metabolic diseases. Its commercial product portfolio includes sparsentan, marketed as FILSPARI, an oral medication approved to reduce the decline of kidney function in adults with primary Immunoglobulin A nephropathy. The company also markets tiopronin tablets, under the brand names Thiola and Thiola EC, to treat cystinuria, a rare genetic disorder that causes recurring kidney stones. Additionally, the company advances clinical-stage candidates such as sparsentan for focal segmental glomerulosclerosis and pegtibatinase for classical homocystinuria. It provides these treatments to patient populations with severe, unmet medical needs.
Company profile, executives and historyTravere Therapeutics stock: common questions
What is Travere Therapeutics's stock price?
TVTX closed at $51.56 on Nov 12, 2026, down 0.92% on the day. Over the past 52 weeks it traded between $22.59 and $68.73.
What is Travere Therapeutics's market cap?
Travere Therapeutics was worth $4.86B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TVTX's P/E ratio?
Travere Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.29), so it has no meaningful P/E ratio.
How much revenue does Travere Therapeutics make?
Travere Therapeutics reported revenue of $651.04M for the twelve months to Sep 30, 2026, up 49.4% from a year earlier.
Does Travere Therapeutics pay a dividend?
No. Travere Therapeutics has not paid a cash dividend over the last twelve months.
When does Travere Therapeutics report earnings next?
Travere Therapeutics is expected to report Q4 FY2027 results on Feb 18, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has TVTX stock performed over the past year?
Including dividends, TVTX returned +41.4% over the past year, against +12.0% for the S&P 500.
How many TVTX shares are sold short?
10M shares were sold short at the latest FINRA report, 10.30% of the float, or 4.7 days of average trading volume.
Who are Travere Therapeutics's competitors?
Companies most similar to Travere Therapeutics by business, industry and size include MIRM, RARE, KNSA, BBIO, IONS.
See a number that looks wrong?